Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 487,641 shares of the biopharmaceutical company’s stock after selling 15,043 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Gilead Sciences were worth $39,509,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of GILD. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $147,000. Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares in the last quarter. Rowland & Co. Investment Counsel ADV purchased a new stake in Gilead Sciences in the 2nd quarter worth $153,000. Finally, Capstone Investment Advisors Netherlands B.V. purchased a new stake in Gilead Sciences in the 2nd quarter worth $172,000. 75.94% of the stock is owned by institutional investors and hedge funds.
Several brokerages have commented on GILD. Mizuho reiterated a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. BMO Capital Markets reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $85.03.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $79.02 on Friday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The company has a market cap of $103,190.00, a P/E ratio of 8.99, a P/E/G ratio of -1.68 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the prior year, the company posted $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.63%. Gilead Sciences’s payout ratio is 23.66%.
In other news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 50,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the sale, the insider now owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock worth $34,072,567 in the last 90 days. 1.30% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Holdings Decreased by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/14/loring-wolcott-coolidge-fiduciary-advisors-llp-ma-sells-15043-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.